LAB
NASDAQ · Life Sciences Tools & Services
Standard Biotools Inc
$0.83
+0.02 (+2.42%)
Financial Highlights (FY 2026)
Revenue
81.58M
Net Income
-71,622,506
Gross Margin
49.9%
Profit Margin
-87.8%
Rev Growth
-4.5%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 49.9% | 49.9% | 33.5% | 33.5% |
| Operating Margin | -129.2% | -116.3% | 10.2% | 9.7% |
| Profit Margin | -87.8% | -83.4% | 8.2% | 10.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 81.58M | 85.41M | 337.87M | 394.49M |
| Gross Profit | 40.68M | 42.59M | 113.16M | 132.12M |
| Operating Income | -105,405,561 | -99,314,284 | 34.61M | 38.43M |
| Net Income | -71,622,506 | -67,483,516 | 27.76M | 42.76M |
| Gross Margin | 49.9% | 49.9% | 33.5% | 33.5% |
| Operating Margin | -129.2% | -116.3% | 10.2% | 9.7% |
| Profit Margin | -87.8% | -83.4% | 8.2% | 10.8% |
| Rev Growth | -4.5% | -4.5% | +3.9% | -1.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 97.1K | 97.1K | 57.07M | 49.88M |
| Total Equity | 161.85M | 161.85M | 239.14M | 240.02M |
| D/E Ratio | 0.00 | 0.00 | 0.24 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -96,542,614 | -96,017,047 | 49.10M | 55.88M |
| Free Cash Flow | — | — | 19.25M | 25.05M |